Dr. Murthy on the Potential Benefits of Treatment De-Escalation in Ph+ B-ALL

Video

Guru Subramanian Guru Murthy, MD, MS, discusses the potential benefits of treatment de-escalation in Philadelphia chromosome–positive B-cell acute lymphoblastic leukemia.

Guru Subramanian Guru Murthy, MD, MS, assistant professor, Hematology, Medical Oncology, Medical College of Wisconsin, discusses the potential benefits of treatment de-escalation in Philadelphia chromosome (Ph)–positive B-cell acute lymphoblastic leukemia (B-ALL).

Ph-positive B-ALL is an aggressive subtype of B-ALL, Murthy says. Treatment for fit patients consists of intensive chemotherapy plus a TKI followed by bone marrow transplant. Patients who achieve remission and undergo transplant are often effectively cured of their disease, but they can receive maintenance therapy with a TKI, Murthy explains.

However, only a proportion of patients with Ph-positive B-ALL, many of whom are older, are fit enough to undergo this intensive treatment regimen, Murthy says. As such, evaluating a de-escalated approach could be beneficial for patients who cannot tolerate intensive chemotherapy.

Data have demonstrated that adding a TKI to chemotherapy improves rates of remission and outcomes among patients with Ph-positive B-ALL; however, equally robust data suggest that adding a TKI to steroids yields high rates of complete responses, Murthy says. Moreover, the latter approach is well tolerated and allows some patients to become eligible for transplant. With the addition of new agents like blinatumomab (Blincyto) to the armamentarium, de-escalation strategies under investigation are becoming more appealing treatment options, Murthy concludes.

Related Videos
Jaime R. Merchán, MD, Sylvester Comprehensive Cancer Center
Rona Yaeger, MD
Mitchell S. Cairo, MD, and Sergio Giralt, MD, experts on veno-occlusive disease
Jeremy L. Ramdial, MD, assistant professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Alexandra Gomez Arteaga, MD, Weill Cornell Medicine/New York-Presbyterian Hospital
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Alice Bertaina, MD, PhD
Jeffery Auletta, MD, The Ohio State University College of Medicine
Betty Hamilton, MD, Cleveland Clinic
Stephanie Lee, MD, MPH, Fred Hutchinson Cancer Center